Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Sanofi Ord Shs SNYNF

Healthcare

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more

Add To Watchlist

Recent & Breaking News (OTCPK:SNYNF)

MannKind, Sanofi Reach Agreement on AFREZZA; Sanofi to Purchase $10.2M Worth of Insulin from MannKind

Benzinga.com November 9, 2016

Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease

Business Wire November 4, 2016

Can Cempra Clear Solithera Hurdle After FDA Reveal?

Benzinga.com November 2, 2016

Regeneron and Sanofi Receive Complete Response Letter from FDA for Sarilumab, an Investigational Treatment for Rheumatoid Arthritis

PR Newswire October 28, 2016

Sanofi CFO Interview - Q3 2016 Results (Video)

PR Newswire Europe Non Regulatory October 28, 2016

Sanofi Announces Strong Q3 2016 Results

GlobeNewswire October 28, 2016

6 Big Pharma Companies Left To Report September Quarterly Figures

Benzinga.com October 25, 2016

Healthcare Stocks Technical Reports -- Immune Pharma, Sanofi, Shire, and Nobilis Health

PR Newswire October 17, 2016

Lexicon Pharma Offers 'A 2-Part Story With Upside Prospects'

Benzinga.com October 7, 2016

New Survey Reveals the Widespread and Serious Impact of Moderate-to-Severe Atopic Dermatitis on People Living with the Disease

PR Newswire October 5, 2016

A Reason To Say Oui To The France ETF

Benzinga.com September 29, 2016

Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA

PR Newswire September 26, 2016

Treatment Effects Maintained Over Six Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials

Business Wire September 16, 2016

Results from 1,000-Patient, Global Real-World Patient-Reported Outcomes Study of Sanofi Genzyme’s Aubagio® (teriflunomide) in Patients with Relapsing Multiple Sclerosis Demonstrate High Levels of Treatment Satisfaction

Business Wire September 15, 2016

Toujeo® Demonstrates a More Stable Profile and Lower Within-day Variability Compared to Insulin Degludec

PR Newswire Europe Non Regulatory September 15, 2016

Watch These 5 Huge Put Purchases In Thursday Trade

Benzinga.com September 15, 2016

Sanofi's Toujeo(R) Demonstrated a Consistently Lower Rate of Hypoglycemia Compared to Lantus(R) at All Levels of HbA1c control

PR Newswire Asia September 13, 2016

Sanofi's Toujeo® Demonstrated a Consistently Lower Rate of Hypoglycemia Compared to Lantus® at All Levels of HbA1c control

PR Newswire Europe Non Regulatory September 13, 2016

Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016

PR Newswire August 29, 2016

Mylan Is Offering An EpiPen Savings Card, But A Lot Of People Will Still Get Screwed

Benzinga.com August 26, 2016